1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is a neurodegenerative dementia that currently affects more than 40 million people worldwide and is expected to affect more than 131 million people by 2050 ([@bib208]). A deeper understanding of its pathophysiology and potential risk factors is critical to develop effective strategies at preventing or delaying development of AD. Intriguingly, stress, sleep disturbance, and circadian rhythm disruption share many common molecular signaling and anatomic pathways that promote the neurodegeneration of AD. For example, the hypothalamus-pituitary-adrenal (HPA) axis -- the main mediator of stress -- is regulated by the circadian rhythm ([@bib75]). In particular, cortisol levels exhibits circadian fluctuations ([@bib47]) and is elevated and deregulated in people with AD ([@bib21]; [@bib101]; [@bib257]; [@bib206]). Stress, sleep disturbance, and circadian disruption interact at many levels to affect neurogenesis, neuroinflammation, and metabolic disruption. In this review, we will discuss circadian rhythm, sleep, and stress physiologies, their bidirectional relationships, and how these interactions promote the development of AD.

2. Physiology of circadian rhythms, sleep and stress {#sec2}
====================================================

2.1. Circadian rhythms {#sec2.1}
----------------------

Living organisms evolved to adopt a circadian rhythm (*circa-*: about, *-dia*: a day) that matches with the light-dark cycle for their protection, feeding, mating and survival ([@bib261]). In humans, the intrinsic period of the circadian rhythm is slightly longer than 24 h while in mice, its period is about 23.5 h ([@bib229]). This period compresses daily to 24 h by using cues from the environment, such as light, and from the organism\'s behavior, such as feeding and activity ([@bib51]). The circadian system governs several physiologic functions, such as sleep and wake, activity, temperature, and cognitive function ([@bib292]).

At the molecular level, the circadian rhythm is controlled by oscillations of transcriptional-translational negative feedback loops ([@bib236]). Brain and Muscle ARNT-Like-1 (BMAL1) heterodimerizes with Circadian Locomotor Output Cycles gone Kaput (CLOCK), forming a complex that binds to E-box enhancers of circadian-controlled genes. The CLOCK/BMAL1 heterodimer also activates transcription of Period (*Per*) and Cryptochrome (*Cry*), forming the positive-limb of the loop. Per and Cry heterodimerize and inhibit the Clock-BMAL1 heterodimers, thereby inhibiting their own transcription and forming the negative loop ([@bib127]). In addition, an accessory loop is formed by CLOCK/BMAL1 heterodimers enhancing transcription of *ROR* and *REV-Erb* genes. These genes bind to the RORE region of the *BMAL1* gene and regulate the core circadian gene loop ([@bib130]). Colcontrol sleep and wakecycleslectively, these interwoven loops result in rhythmic oscillations of circadian-controlled gene expression. This feedback loop is the molecular basis of the circadian rhythm and sets the timing and period of central and peripheral clocks in animals.

Nearly all peripheral tissues in the body have a circadian rhythm -- with the ability to oscillate independently ([@bib230]; [@bib188]), at least in the short term -- and are regulated and synchronized by a central circadian pacemaker, the suprachiasmatic nucleus (SCN) ([@bib224]; [@bib2]). This master clock is in the ventral most part of the hypothalamus, just above the optic chiasm. The SCN sends output signals via direct or indirect neural projections or humoral controls to areas to regulate timing and period of peripheral rhythms ([@bib2]; [@bib53]). For example, the SCN sends signals to the various nuclei in the hypothalamus and areas beyond that control sleep and wake cycles ([@bib238]; [@bib41]), temperature ([@bib24]), and hunger/satiety ([@bib112]).

The SCN receives input from various time cues to regulate the circadian timing and synchronize the peripheral circadian rhythms. Specifically, the SCN receives light exposure input from the retina by a direct pathway. In the retina are specialized melanopsin-containing retinal ganglion cells (mRGCs) ([@bib78]) which carry light input via the retinohypothalamic tract to the SCN ([@bib15]; [@bib89]). Light exposure can compress or expand the circadian period and therefore change the timing, or phase, of the circadian rhythm; the direction and magnitude of change depend on the timing, intensity, and duration of light exposure ([@bib121]). In blind people who lack light signaling to the SCN, the circadian period can oscillate closer to its intrinsic period, resulting sleep-wake cycle that is slightly longer than 24 h ([@bib220]). Another example of a timing input to the SCN is melatonin. Melatonin is naturally produced by the pineal gland in a circadian manner and is under control by the SCN ([@bib264]). During the day, melatonin levels are low; at night, melatonin levels rise just prior to circadian timing for sleep, peak during sleep, and fall around the circadian timing for wake ([@bib141]). Melatonin feeds back to the SCN to adjust timing of the circadian rhythm. Melatonin administration can also adjust the phase of circadian rhythm depending on the timing and dose ([@bib142]).

Circadian rhythm outputs can be measured in various means. For example, the rest/activity rhythm, which can be used as a proxy for sleep/wake rhythms, can be measured using actigraphy over several days ([@bib5]). Melatonin levels can be measured in plasma ([@bib11]) or saliva ([@bib276]), and melatonin metabolites can be measured in urine ([@bib11]). These outputs can be used to examine the period, phase, and amplitude of the circadian rhythm. In people with circadian rhythm sleep-wake phase disorders, the circadian timing of the sleep-wake cycle is misaligned, either early or late, with respect to the environment ([@bib4]). Loss of amplitude and therefore rhythmicity of the sleep-wake rhythm results in irregular sleep-wake disorder, in which patients -- typically those with dementia -- have no major bout of sleep and instead have frequent bouts of sleep and bouts of wake throughout the 24-h cycle ([@bib4]).

The circadian system also influences cognitive function. Cognitive performance varies throughout the 24-h cycle day and is high during the day about 24 hrs after waking except for a dip in the afternoon and low at night ([@bib282]; [@bib25]). Several cognitive processes are affected by circadian timing; for reviews, see ([@bib290]; [@bib133]). The SCN controls cognitive function indirectly through its effects on sleep and wakefulness and perhaps through more direct effects ([@bib238]; [@bib41]; [@bib290]). Circadian misalignment, where the timing of daily activities -- such as sleep and wake -- are not aligned to the endogenous circadian timing, results in impaired cognitive function. Chronic jet lag leads to cognitive performance and is associated with increased cortisol levels ([@bib39]; [@bib40]) Experimental jet lag in rodents result in long term cognitive deficits ([@bib74]). Thus when circadian rhythm is misaligned and circadian amplitude is lowered in old age and dementia patients, it also coupled with cognitive impairment ([@bib244]).

2.2. Sleep {#sec2.2}
----------

A vast array of literature has described various functions of sleep, including cognitive function, metabolism, and inflammation. Although a detailed review of the structure, function and regulation of sleep are beyond the scope of this paper, we will describe in general the physiology, anatomy, and functions of sleep as it relates to cognitive function and AD.

Sleep and wake states are regulated by a 2-process model: the circadian system, as described above, and a homeostatic process ([@bib18]). The homeostatic drive for sleep indicates that the greater period of wakefulness, the greater need for sleep an organism has. As the sleep homeostat increases, the circadian alerting system also increases to maintain wakefulness during the day. At night, the circadian alerting signal drops; this, in conjunction with a high sleep need, results in transition to sleep ([@bib18]).

From a brain physiology level, sleep is characterized by two general sleep states measured by polysomnography: non-rapid eye movement sleep (NREM) -- which consists of three stages, N1, N2, and N3 -- and rapid eye movement (REM) sleep. As NREM sleep becomes deeper, there is slowing of electroencephalographic frequencies and increasing synchronization of cortical neuronal activity. At its deepest point -- stage N3 or slow wave sleep (SWS) -- the neuronal synchrony appears as large slow wave activity on the electroencephalogram ([@bib14]). SWS is considered a marker of the sleep homeostat, as it rebounds during recovery sleep after prolonged wakefulness ([@bib55]). REM sleep is characterized by cortical desynchrony and rapid eye movements and is associated with dream states ([@bib14]).

From an anatomical standpoint, sleep and wake states are controlled by a balance between sleep-promoting nuclei and wake-promoting nuclei. The sleep-promoting nuclei are the GABAergic ventrolateral preoptic (VLPO) and the median preoptic area located in the hypothalamus ([@bib259]). These areas inhibit the wake-promoting centers in the lateral hypothalamus, the tuberomammillary nucleus, and several brainstem nuclei ([@bib259]). Conversely, the monoaminergic wake-promoting nuclei inhibit the VLPO ([@bib259]). These two systems form a flip-flop switch, in which the orexinergic neurons in the lateral hypothalamus promote the activity of wake-promoting nuclei and inhibit the VLPO, thereby stabilizing the wake state ([@bib227]). In addition, the VLPO also receives input from the SCN to regulate circadian rhythm of sleep/wake states ([@bib225]). REM sleep is generated by neurons in the peri-locus ceruleus area and sublaterodorsal area in the upper pons. The sublaterodorsal area projects to the basal forebrain and cortex, leading to dream states, and to medullary and spinal cord areas to inhibit movements during REM sleep ([@bib200]).

Sleep plays an important role in various cognitive functions. Acute sleep deprivation impairs attention and vigilance, but even chronic sleep deprivation of 6 h nightly can cumulatively impact cognitive functions ([@bib57]). Beyond just sleep duration, SWS and REM sleep each have roles in impacting cognitive performance. SWS has been linked primarily to learning and memory, particularly declarative memory, which includes remembering facts and events ([@bib284]; [@bib139]). In contrast, REM sleep appears to play a role in non-declarative memory, or procedural memory, and emotional memory ([@bib19]). However, some data suggest that SWS and REM sleep have complementary roles in memory consolidation, as SWS does also benefit procedural memory ([@bib170]). In addition, sleep spindles, which are predominantly in stage N2 and SWS, are also linked to cognitive function and appear to be involved in memory consolidation during sleep ([@bib211]).

Much research has focused on the role of SWS in memory. On a physiologic level, two hypotheses -- which are not mutually exclusive -- have emerged to explain sleep\'s role in memory consolidation. The synaptic homeostasis hypothesis postulates that during wakefulness, synaptic strength increases, and during sleep -- particularly SWS -- synaptic strength decreases ([@bib266]). This downscaling maintains synaptic homeostasis. The active system consolidation model postulates that slow wave activity strengthens synapses that are reactivated during sleep and facilitates transfer of memory from the hippocampus to neocortex for long-term storage ([@bib54]).

2.3. Stress {#sec2.3}
-----------

Stress is an aversive stimulus that elicits physiological responses both at the central (arousal, vigilance, attention) and peripheral systems (metabolism and oxidation) to minimize the effects of that stressor. Stressors acutely engage the autonomic nervous system to prepare the body for the classic "fight or flight" response to avoid immediate danger ([@bib271]). Chronic effects of stressors engage a slower kinetic neuroendocrine response of the hypothalamus-pituitary-adrenal (HPA) axis, leading to deleterious effects on the organs.

The HPA axis is the major pathway for the stress response and is activated in allostatic response to return the body to homeostatic state. The hypothalamus releases two neuro-hormones: corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) into the blood that directly activates the pituitary via the hypophysial portal system. These two hormones stimulate the release of adrenocorticotropic hormone (ACTH) into the main circulation system. ACTH then stimulates the adrenal cortex to release glucocorticoid in rodents and cortisol in humans ([@bib251]) Glucocorticoid, in turn, provides negative feedback by binding to the mineralocorticoid receptors (MRs) and the glucocorticoid receptors (GRs) both in the hypothalamus and pituitary gland and shuts off its own production. Glucocorticoid (G) is a steroid hormone whose primary function is to facilitate the metabolism of glucose, protein and fat to supply energy for the body during stressful events. Besides these specific effects, G binds to GR and activates various signaling pathways with wide-range effects influencing learning and memory, immune response, arousal, and others. For the healthy individual, cortisol rapidly increases during a stressful event and quickly declines following the removal of an acute stressor.

The effects of both acute and chronic stress on the brain are very broad and beyond the scope of this review but are covered in previous reviews ([@bib271]; [@bib43]). Psychological and physical stressors incur a wide array of deleterious effects such as sleep and circadian rhythm disruption, neuroinflammation, oxidative stress and more. Specifically, the role of stress on AD has been intensively and extensively discussed in these reviews ([@bib206]; [@bib156]; [@bib105]; [@bib70]). Chronic stress has detrimental consequences on the brain and is thought to be a contributing to neurodegenerative disease. Both chronic psychological and physical stress also lead to cellular stress. Multiple insults from the environment could damage the macromolecules such as DNA, lipids, and proteins. These two pathways then integrate signaling and elicit appropriate responses from the cellular stress signaling response network. For example, if DNA is damaged from stress, chromatin modeling machinery will be recruited for DNA repair. Eventually, if all attempts to nullify the environment stressor fail, cell apoptosis engages as the final solution ([@bib134]).

2.4. Interactions between circadian rhythms, sleep, and stress {#sec2.4}
--------------------------------------------------------------

Stress, circadian rhythms, and sleep all have interactive relationships ([Fig. 1](#fig1){ref-type="fig"}). For example, psychological stressors result in sleep fragmentation and reduced sleep duration, SWS, and REM sleep ([@bib125]). One major area where stress responses and sleep and circadian rhythm disruption intersect is the HPA axis and cortisol levels. Sleep restriction and circadian misalignment, such as with shift work, increase the stress response with elevated cortisol levels ([@bib248]) and inflammation ([@bib273]). Circadian misalignment can also result in sleep disruption ([@bib4]) and alter cortisol production ([@bib291]). In turn, cortisol can reset other peripheral rhythms, such as that in adipose tissue ([@bib129]).Fig. 1A model of interactions among sleep disruption, circadian disruption and stress.Fig. 1

Obstructive sleep apnea (OSA) is a sleep disorder that is particularly relevant to stress. OSA is characterized by recurrent obstructions in the upper airway when asleep, leading to intermittent hypoxemia and arousals. The prevalence of OSA increases with age and affects 9% of women and 17% of men age 50--70 years ([@bib202]). With frequent arousals, OSA can cause sleep to be fragmented. OSA impairs cognitive function, especially executive function. Furthermore, OSA may increase cortisol activity ([@bib274]), and greater nighttime cortisol correlates with worse cognitive function beyond that expected for OSA alone ([@bib61]).

The HPA axis and its main effector, cortisol in humans and corticosterone (where glucocorticoid is the main example) in rodents, are also under circadian regulation. The release of G is controlled by a dual-rhythm regulation: circadian rhythm for 24-h control and pulsatile ultradian rhythm for hourly control ([@bib285]). Since the levels of CRF, ACTH, and G are circadian regulated ([@bib75]; [@bib42]), it is not surprising that the level of stress responses is time dependent ([@bib58]). Rodents, which are nocturnal animals, have heightened stress responses at the beginning of the light cycle (when corticosterone is already high) than at the beginning of the dark cycle even with the same stressor ([@bib118]). Furthermore, *Bmal1* ([@bib140]) and *Clock* ([@bib268]) positively regulate the level of glucocorticoid. Ablating the *Bmal1* gene results in lower basal G level and blunted effects on the stress-induced responses ([@bib140]). In contrast, *Cry* represses glucocorticoid production; in the absence of *Cry* gene, glucocorticol is elevated ([@bib7]; [@bib137]).

The molecular clock is critical for adrenal function and therefore HPA axis. Through different experiments, it was unambiguously demonstrated that the molecular clock of the adrenal gland is cell-autonomous. Specifically, the mRNA levels of *Bmal1, Per1,* and *Per2* in the adrenal gland are still rhythmic following hypophysectomy ([@bib62]), while *in vitro* experiments demonstrate that ACTH controls phase setting of the adrenal core molecular clock ([@bib296]). Genetic ablation of *Bmal1* ([@bib245]) or *Per1/Per2* ([@bib196]) demonstrate that rhythmic GC release is due to localized peripheral clock in the adrenal gland. Through the HPA axis and potentially other pathways, the SCN still regulates this peripheral rhythm to control the adrenal activity ([@bib44]). Thus, circadian activity of the adrenal gland is controlled both by the upstream signaling and localized molecular clock machinery.

In short, sleep and circadian rhythm functions modulate the HPA axis in basal conditions; however, under chronic stress, the HPA axis becomes constantly activated and therefore overrides the circadian rhythm control and can disrupt the circadian rhythm. It is reasonable to conclude that these interconnected relationships, when dysfunctional, will form a perpetual feedback loop that synergistically exacerbates pathophysiologic changes in each other.

3. Alzheimer\'s disease (AD) {#sec3}
============================

AD is a progressive dementia associated with complex etiologies and affects an increasing aging population ([@bib100]; [@bib163]). The pathological hallmarks of AD are the extracellular plaques, intracellular tangles, and neuronal loss ([@bib162]; [@bib76]; [@bib85]). Following the identification of amyloid peptide at the core of the plaques, the amyloid precursor protein (APP) and the enzymes that cleave APP were identified ([@bib84]). The mechanistic insights integrated from multidisciplinary discoveries constitute the elements of the of amyloid cascade hypothesis (ACH), which postulates that aberrant accumulation of amyloid beta (Aβ) leads to intracellular fibrillary tangle build up and ultimately cellular death ([@bib85]; [@bib84]). The newly emerged pathological signature of AD is neuroinflammation, which has recently become the center of research interest in AD ([@bib92]; [@bib272]; [@bib213]). Neuroinflammation contributes to formation of plaques and reduction of synapses through over-pruning by the microglia ([@bib97]). Thus, inflammation is a tangible therapeutic avenue ([@bib262]).

The ACH accentuates the role of amyloidosis and places the amyloidocentric perspective at its center, but it is inadequate to fully explain the disease pathologies. For instance, it remains enigmatic as to why there is a long quiescent period, where patients remain asymptomatic for decades despite accumulation of amyloid plaques. Nevertheless, the ACH provides an important frame work for all the recent therapeutic approaches. As such, many clinical trials aimed at reducing amyloid plaques have yielded no tangible successes. Among all the probable confounders, limitations, and technical challenges, one important reason may be the missed therapeutic window; patients even at mild and moderate stage at the time of commencing the clinical trials were already at potentially irreversible stage due to significant synaptic and neuronal losses ([@bib234]; [@bib119]).

Alternative theories were thus engendered to explain the seemingly contradictory evidence, including the temporal course of disease progression and the spatial discordance of the disease. These theories diverge on the origins and the primary factors of AD pathogenesis, yet all evidence converges on the perspective that AD must be detected early to maximize the effectiveness of treatment. Thus, it is imperative to have a reliable, simple, and non-invasive biomarker to detect early stage of AD. One potential early biomarker for detecting AD is sleep and circadian rhythm dysfunction (SCRD). It has been reported many decades ago that some AD patients exhibited confusion in the early evening hours, hence the term "sundowning" ([@bib275]). Recent and mounting evidence further strengthened the connection between SCRD and AD ([@bib96]) as we discuss below.

3.1. The challenges of early detection and treatment of AD {#sec3.1}
----------------------------------------------------------

At the mechanistic level, according to the ACH, Aβ peptides are generated by a sequential protease-mediated cleavage of the APP by β-secretase enzyme 1 (BACE1) followed by γ-secretase. Aβ42 is synaptotoxic and is the main constituent of neuritic plaques. The elevation of Aβ42 initiates a cascade of failure resulting in accumulating intracellular Tau and ultimately neuronal demise ([@bib85]; [@bib234]; [@bib86]). In support of the ACH, people who inherit mutations in the *APP*, Presenilin 1 (*PSEN1*) or *PSEN2* genes produce the longer forms of Aβ peptides (\>42aa) and have an accelerated symptomatic onset. In contrast, most AD patients have late-onset symptoms of dementia with undefined causes. Recent results from genome wide association studies (GWAS) provide several genes that associated with AD ([@bib136]; [@bib181]; [@bib29]); however, the mechanisms between these genes and AD pathophysiology remain to be elucidated.

Much efforts in identifying the genetic underpinnings of AD had yielded only a handful of genes. Mutations in *APP*, *PS1*, and *PS2* were identified as causes of early onset AD but are seen in less than 1% of people with AD overall ([@bib3]). Apolipoprotein E ε4 (APOE ε4) mutation is cause of late onset AD and consistently comes up in many genome wide association studies (GWAS) ([@bib28]; [@bib155]). Genetically, APOE ε4 poses the highest risk factor for late onset AD. We will mention a few important points about APOE. First, APOE encodes for a lipid/cholesterol carrier, a lipoprotein that binds to the APOE receptor ([@bib157]). Individuals with one APOE ε4 allele have a 4-fold higher risk of AD, and those with two alleles have a 10-fold higher risk of AD compared to those without an APOE ε4 allele. Second, the APOE ε2 allele appears to have a protective effect on AD. Recent experiments in mice have shown the APOE ε4 is associated with greater amyloid plaques compared to APOE ε2 isoform ([@bib28]). Third, APOE transcription appears to fluctuate in a circadian manner ([@bib155]); the APOE protein, however, does not fluctuate across the day ([@bib270]), so the significance of these fluctuations and the role of circadian rhythm control on APOE is unclear ([@bib300]; [@bib149]; [@bib298]; [@bib22]; [@bib115]). Fourth, another relevant aspect of APOE is its protective role in oxidative stress. Specifically, a significant increase in lipid peroxidation in plasma and lipoprotein was observed in mice with APOE ablated ([@bib90]). Furthermore, APOE ε4 confers higher risk of cell death compared to APOE ε2 in when cells are exposed to hydrogen peroxide. ([@bib173]). Consistently, freshly dissected prefrontal cortex postmortem tissues of people with AD showed that APOE ε 4 is strongly associated with higher levels of lipid oxidation ([@bib210]). Taken together, these results showed that APOE has an essential role in protecting the cells against oxidative damage in an allele specific manner, where APOE ε2 is the most protective and APOE ε4 is the most harmful allele.

The ACH is not universally accepted for several reasons (for reviews, see ([@bib119]; [@bib94]; [@bib65])). The ACH parsimoniously expounds the temporal and spatial discordance between the region of brain where Aβ and tangles originate. Aβ plaques first appear in the precuneus and the frontal cortex, but hyper-phosphorylated Tau first appears in the entorhinal cortex ([@bib186]). Recently, therapeutic strategies aimed at reducing Aβ peptides, such as the BACE1 inhibitor verubecestat ([@bib184]) and the anti-Aβ antibody treatments (Solanezumab, Eli Lily) ([@bib183]) both failed in phase III clinical trials ([@bib101]). The failures could be due to confounders such as the drug potency, brain penetrance, and stage of AD at the time of treatment ([@bib247]). Results from a new verubecestat phase III trial that treats early stage (or prodromal) patients will be revealed in early 2019, and positive results from this study would corroborate the validity of the ACH. Nevertheless, the ACH accommodates many findings and discoveries thus far. It is the most validated hypothesis providing framework for the mechanistic understanding and potential therapeutic treatments to date ([@bib234]).

Currently available medications for AD only manage symptoms and include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and an NMDA receptor antagonist (memantine) ([@bib150]). Although these drugs show some short-term benefits, the potential side effects (e.g nausea, vomiting, dizziness, loss of appetite, confusion) often outweigh the benefits ([@bib150]; [@bib104]).

Due to the recent litany of failure of pharmaceutical approaches to ameliorate cognitive impairments in mild-moderate AD patients, the current goal is to detect and treat AD before it starts, especially in the quiet prodromal period ([@bib222]). Until recently, the only way to confirm the diagnosis of AD was by post-mortem immunostaining of the brain. It is now possible to detect Aβ plaques in living patients with synthesized PET-scan dyes, e.g. the ^11^C-PIB (Pittsburgh compound B). Although ^11^C-PIB can detect the fibrillary form of Aβ peptides (mainly Aβ40 and Aβ42) ([@bib126]) and was heralded as a new diagnostic tool, current large scale usage of this tool is limited because of availability and cost and is not appealing to the general population due to the use of radioactive tracers ([@bib122]). Innovative and less invasive approaches, such as blood-based biomarkers ([@bib195]; [@bib190]) and retina scans for Aβ deposition ([@bib88]; [@bib131]; [@bib132]), show promise for detection of early signs of AD in general population but are still in their infancy. Alternatively, a wealth of recently accumulating evidence demonstrate that SCRD could serve as early biomarkers ([@bib252]; [@bib31]; [@bib145]; [@bib152]), providing an intriguing possibility to understand the physiology and identify modifiable risk factors to prevent the development or delay the progression of AD.

3.2. Circadian rhythms and AD {#sec3.2}
-----------------------------

Alterations in circadian rhythm function in AD has long been recognized. Most notably, people with AD often develop a loss of the sleep/wake rhythm, resulting in short bouts of wakefulness interspersed with short bouts of sleepiness throughout the 24-h day but no major sleep or wake bout ([@bib288]). This finding has led to further study degeneration of circadian function in AD. In general, such dysfunction may occur due to loss of time cues to the SCN, dysfunction in the SCN itself, or changes in the output rhythms directly, which also lead to impaired feedback to the SCN.

Failure of appropriate inputs to the SCN occur in AD and may also play a role in the associated circadian rhythm disruption. People with AD experience decreased light exposure, even if not institutionalized ([@bib67]). Beyond having less light exposure, signaling of light to the SCN may be impaired, as mRGCs are significantly reduced in AD patients ([@bib66]). Evidence from optical coherence tomography and post-mortem histological analysis of AD patients show a significant reduction of nerve fiber layer thickness and a reduced number of mRGCs ([@bib179]; [@bib178]). These findings were further corroborated by multiple lines of evidence, both in humans and mice, that Aβ plaque deposits and phosphorylated Tau are present in the retina ([@bib132]; [@bib297]; [@bib192]). Reduction of mRGCs may impair proper SCN entrainment, and protecting the mRGCs from degeneration could potentially improve circadian function in AD and perhaps delay the progression of AD.

The SCN anatomically and functionally deteriorates in aging and neurodegenerative diseases ([@bib166]), and the degree of SCN degeneration correlates with the degree of circadian disruption ([@bib87]; [@bib253]). The number of neurons positive for vasoactive intestinal peptide (VIP) and arginine-vasopressin (AVP) are significantly reduced in the SCN of AD patients compared to control cohorts in post-mortem analysis ([@bib279]; [@bib256]). Moreover, there is a high concordance between the degree of degeneration of these SCN-specific neurons and the severity of sleep-wake disruption. Interestingly, AVP is an anxiogenic and purported to mediate long term stress and depression which often seen in AD ([@bib16]). The loss of these critical neurons results in asynchronous firing patterns among SCN neurons and diminished amplitude outputs, thus rendering the SCN unable to synchronize the peripheral clocks. Degeneration of the SCN invariably disrupts the circadian rhythm with many consequences, including sleep fragmentation ([@bib148]), memory impairment ([@bib205]), and metabolic changes ([@bib113]).

Besides the sleep-wake cycle, other disrupted circadian rhythms, including a delayed phase of the core body temperature rhythm ([@bib203]), low amplitude of the melatonin rhythm ([@bib281]), and changes in circadian gene expression ([@bib32]) and circadian period ([@bib235]; [@bib231]) are also observed in AD patients. Conversely, recent evidence has implicated that circadian rhythm disruption is not only consequence of AD but also may increase the risk of AD ([@bib185]; [@bib187]). For example, alterations in the rest/activity rhythm is a predictor of dementia in the elderly ([@bib267]). In addition, variations in the coding sequence of *BMAL1* ([@bib38]) or *CLOCK* ([@bib35], [@bib36]; [@bib295]) genes increase the propensity of developing AD. By definition, these studies only demonstrate a correlation between the risk of getting the disease and having a variation in the gene but do not imply causation.

In short, the SCN orchestrates a complex symphony of neuronal activity. When the SCN function is compromised as in AD patients, the symphony becomes cacophony. The SCN is "the strange case of Dr. Jekyll or Mr. Hyde", when functional, it is beneficial, but when it breaks down, it becomes a stressor, leading to sleep disruption and sleep fragmentation.

3.3. Sleep and AD {#sec3.3}
-----------------

Sleep disruption manifests in several ways in AD. It is not surprising that AD patients frequently exhibit nighttime sleep fragmentation and daytime sleepiness. With aging, sleep tends to become more fragmented and some sleep stages, particularly SWS, decline. These changes are accentuated in AD, and furthermore, stage REM sleep declines ([@bib159]; [@bib20]; [@bib109]). These sleep problems are also manifestations of underlying circadian rhythm disturbances, such as low amplitude of the rest and activity rhythm, the degree of which correlates with the degeneration of the SCN ([@bib87]; [@bib253]). Sleep fragmentation may also be related to Aβ accumulation and neuronal loss in structures that regulate sleep-wake states, such as the intermediate nucleus of the hypothalamus, the human homologue of the VLPO ([@bib146]). Moreover, animal models that were engineered to express human Aβ peptides reveal that a high level of Aβ induces fragmented sleep in *Drosophila* ([@bib73]). Other sleep architecture changes, such as a decline in SWS is seen even in people with mild cognitive impairment, who are at risk for developing AD ([@bib283]). This change may be of particular importance as SWS plays a role in cognitive performance as discussed above ([@bib283]).

Recent evidence has shown that sleep disruption is a risk factor for AD. Sleep disruption can begin years or even decades before the onset of AD. Sleep fragmentation impairs memory consolidation in animals ([@bib219]) and has been demonstrated to be a risk for AD ([@bib56]; [@bib144]). Cognitively normal individuals with self-reported sleep problems have a higher likelihood of having AD biomarkers such as lower levels of Aβ42 and higher levels of total Tau and phosphorylated-Tau in the cerebrospinal fluid ([@bib249]). Several studies have shown that rest/activity rhythm alterations predict cognitive decline ([@bib278]) and mild cognitive impairment and dementia ([@bib267]). Recently, a large meta-analysis reported that both insomnia and sleep disordered breathing increase the risk of AD by 49% ([@bib239]). Although these data do not demonstrate casual effects, recently there are mechanistic studies pointing to this possibility ([@bib10]; [@bib217]; [@bib153]). For example, sleep deprivation decreases leptin levels and increases ghrelin levels ([@bib260]); these two hormones appear to play protective roles from Aβ peptides.

Two seminal discoveries provide mechanistic insights between circadian rhythm, sleep and AD through production and clearance of Aβ: 1) the relationship between the sleep-wake cycle and Aβ metabolism and 2) clearance of Aβ from the brain. First, the sleep-wake cycle drives the oscillations of interstitial fluid Aβ peptides (mainly Aβ40 and Aβ42). Aβ level peaks during the active phase and reaches a trough during the sleep phase both in mice and in humans ([@bib217]; [@bib102]). During sleep deprivation, Aβ levels increase in humans and mice ([@bib217]; [@bib9]; [@bib117]). In contrast, inhibition of neuronal activity by tetrodotoxin significantly reduces the level of interstitial fluid Aβ peptide ([@bib45]). Second, through experiments using *in vivo* two-photon imaging, it was shown that clearance of Aβ peptides occurs through the elusive glymphatic system, which is analogous to the lymphatic system but in the central nervous system and mediated by the glia. Toxic metabolites egress through bulk flow that carries metabolic wastes, including Aβ and Tau, more efficiently during natural or substance-induced sleep than during wakefulness ([@bib294]).

Blood brain barrier (BBB) disruption may also be a mechanism by which sleep disruption promotes AD. Breakdown of the BBB -- a finding consistently observed in people with AD ([@bib301]) -- can be detected before any symptomatic onset of cognitive impairment and any AD pathology in the brain ([@bib175]) and even before changes in cerebrospinal fluid Aβ and tau levels ([@bib174]). Chronic sleep restriction induces the breakdown of the BBB in rodents ([@bib77]; [@bib91]). Selective deprivation of REM sleep also impairs BBB integrity ([@bib77]). Further studies are needed to clarify the role of BBB integrity and AD and the effect of chronic sleep disruption on the BBB.

The mechanism of sleep disruption on Aβ following one night of sleep deprivation could be due to either overproduction of Aβ, reduced clearance or a combination of both. Bateman and colleagues present evidence that sleep deprivation increases production of Aβ peptides ([@bib153]). Experimental sleep disruption, either pharmacologically ([@bib117]) or with sounds ([@bib111]), also increases Aβ levels. Although these studies cannot distinguish between increased Aβ production and impaired glymphatic clearance of Aβ peptides, wakefulness does appear to promote Aβ production. Aβ peptide levels increase in the barrel cortex when mouse whiskers are physically stimulated, and removal of whiskers (thereby inhibiting neuronal activity) decreases Aβ peptide level ([@bib13]). Collectively, these results suggest that neuronal activity drives the production of Aβ peptides. Although the biological function of Aβ42 is not fully understood, evidence indicates that Aβ peptides inhibit synaptic transmission through NMDA receptor activation, perhaps to dampen neuronal activity ([@bib114]). Whether the daily oscillation of Aβ peptide levels has any functional role remains to be explored; however, disruption of Aβ peptide oscillations increases the likelihood of plaque accumulation ([@bib217]; [@bib9]; [@bib117]). Furthermore, impaired clearance of Aβ could play a role. Indeed, it was demonstrated that the glymphatic system was suppressed before an abundant accumulation of Aβ plaques ([@bib201]), supporting impaired glymphatic clearance as a mechanism in AD pathophysiology. More studies are needed to determine how well glymphatic system clears Aβ and Tau in sleep-deprived and sleep-fragmented states to conclude with certainty the roles of Aβ production and clearance.

Levels of Aβ and sleep fragmentation appear to have a bidirectional relationship. While sleep disruption increases Aβ levels, Aβ may promote sleep disruption. Aβ peptides promote degradation of BMAL1 and Creb-Binding Protein (CBP), which causes further sleep and circadian disruption in an AD mouse model ([@bib246]). Therefore, sleep fragmentation increases Aβ release -- increasing the risk of amyloid plaque formation and neuronal injury -- which in turn exacerbates sleep fragmentation and disturbance. If such damage occurs in structures controlling sleep and wake, further sleep fragmentation would ensue, worsening the neurodegenerative process ([@bib108]).

3.4. Circadian rhythms, sleep, stress and AD {#sec3.4}
--------------------------------------------

Stress has been extensively demonstrated to be a contributing factor to AD ([@bib156]; [@bib70]; [@bib50]; [@bib182]; [@bib80]). Briefly, stress alters the allostatic load and effects the brain directly at three levels. At the cellular level, it alters proteostasis -- as observed in hyperphosphorylation and aggregation of Tau -- and causes epigenetic changes in neuronal DNA ([@bib182]). At the tissue level, stress causes reduction of synaptic density and number of neurons and accumulation of extracellular Aβ peptides ([@bib182]). Stress induces changes in the peripheral organs where it alters metabolic, cardiovascular, and gastrointestinal physiology and deregulates the immune system ([@bib182]). These effects indirectly worsen brain homeostasis and increase susceptibility to AD ([@bib182]). In particular, chronic stress activates the HPA axis resulting in many deleterious effects such as increased Aβ plaque load and Tau pathology, memory impairment, and neurodegeneration ([@bib27]). Stress also increases several cytokines and impairs neurogenesis in rodent AD-models ([@bib215]). In humans with AD, cortisol is associated with higher rate of cognitive decline, though this relationship was not seen in people without dementia ([@bib50]).

Given the intertwined nature of sleep and circadian rhythm disruption and stress and each of their direct relationships with AD pathology, the intersection of these factors likely promotes AD pathology. Circadian rhythm disruption affects sleep and misalignment of other physiologic rhythms, which may worsen stress. Sleep disruption increases stress, and stress increases sleep disruption, both leading to downstream effects on AD pathogenesis. Different forms of stresses alter sleep architecture and activate the HPA axis ([@bib199]). Stress-inducing paradigms such as social defeat, restraint or immobilization, foot shock, or water submersion demonstrate the detrimental effects of stress on sleep ([@bib223]).

Remarkably, in humans, one night of sleep deprivation increases cortisol levels and potentiates the HPA axis ([@bib171]). In mice, acute stress potentiates the HPA axis response but chronic stress blunts the HPA axis response ([@bib193]; [@bib82]). On the other hand, chronic stress due to isolation housing and acute stress due to restraints significantly elevate Aβ via a CRF-dependent mechanism ([@bib116]). Multiple studies have shown that sleep deprivation increases cellular oxidative stress ([@bib52]; [@bib164]; [@bib209]). Thereafter, cellular oxidative stress by reactive oxygen and reactive nitrogen species instigates AD pathogenesis ([@bib254]). Accordingly, oxidative damage was the first event to be observed in human post-mortem AD brains ([@bib194]). Furthermore, oxidative stress as indicated by lipid peroxidation presages plaque deposition in an amyloidosis mouse model ([@bib207]).

OSA is another potential link between stress and AD. Sleep disordered breathing, including OSA, raises the risk of incident AD by 20% ([@bib239]). The sleep fragmentation in OSA may increase neuronal activity and Aβ release and impair Aβ clearance. In addition, the intermittent hypoxemia has several effects that can raise risk of neurodegeneration. For example, intermittent hypoxemia upregulates β-secretase, resulting in increased cleavage of APP to Aβ42 ([@bib191]; [@bib240]). Cerebrospinal fluid in people with OSA have decreased Aβ42 and increased tau protein, findings that like those with AD ([@bib110]). Furthermore, intermittent hypoxemia increases oxidative stress, reactive oxygen and nitrogen species, and inflammation, promoting AD pathophysiology ([@bib93]), cortical thinning ([@bib107]), and neuronal apoptosis ([@bib79]; [@bib189]).

Interestingly, the anatomical areas controlling the sleep-wake cycle, including the locus coeruleus (LC), the VLPO, and others, are damaged by the stress-response in the setting of AD in a manner that can worsen AD pathophysiology ([@bib49]; [@bib228]). For instance, LC is a wake-promoting center and is activated when exposed to stress-induced paradigms ([@bib169]). Moreover, the LC and VLPO are degenerated in AD, further strengthening the connection between stress and the sleep-wake cycle ([@bib87]; [@bib146]; [@bib228]; [@bib165]; [@bib226]). Intriguingly, the LC was demonstrated to be the first region of the brain to be damaged in AD patients ([@bib165]). In support of this notion, stress increases phosphorylated Tau, which is a precursor to neurofibillary tangle and is mediated by CRF ([@bib135]). Furthermore, stress increases phosphorylated Tau in the LC, which might explain why this region is subjected to deterioration in stress-induced circadian disruption conditions ([@bib135]). It is currently a conundrum to determine which comes first, stress or sleep disruption, to initiate the pathogenesis of AD. However, the evidence supports the notion that stress, sleep disturbance, and circadian disruption collaboratively and synergistically exacerbate AD pathogenesis and cognitive dysfunction in people with AD.

4. Multiple interactions and potential mechanisms {#sec4}
=================================================

Collectively, each of these factors, sleep, circadian rhythm, and stress could independently or co-operatively influence the pathogenesis or maintenance of AD. To recapitulate the complex interwoven nature of these two factors: the sleep-wake cycle and the circadian rhythm are tightly intertwined, and stress has bidirectional relationships with both circadian rhythm dysfunction and sleep disturbance. Consequently, there are multiple converging pathways where sleep and circadian disruption can synergistically influence on AD pathophysiology ([Fig. 2](#fig2){ref-type="fig"}); we will discuss these pathways below.Fig. 2A model of the interaction of stress, sleep disturbance, and circadian rhythm disruption promotes Alzheimer\'s disease pathogenesis.Fig. 2

4.1. HPA axis {#sec4.1}
-------------

The HPA axis is preeminent converging pathway and was discussed above. However, a few important additional points should be mentioned. First, the HPA axis activation promotes AD pathogenesis ([@bib206]). Indeed, in a 35-year longitudinal population study the investigators found midlife stress significantly increases the risk of developing AD ([@bib156]; [@bib105]). In particular, stress increases CRF release which then increases γ-secretase activity, resulting in higher Aβ production ([@bib198]). In addition, cortisol levels in AD patients are high compared to controls. Although treatment aimed at reducing cortisol levels, such as by taking dex-amethasone failed to yield any positive effect in AD patients ([@bib258]), approaches to modulate and decrease the HPA axis activity could still be a viable and promising venue for treating AD ([@bib70]), particularly if started prior to symptom onset. Second, Aβ promotes HPA axis activation. Intracerebroventricular injection of Aβ peptides increase corticosterone and elevated HPA axis activity. These results demonstrate that the HPA axis contributes significantly to the development and perhaps the progression of AD ([@bib21]). Taken together, the activation of the HPA axis appears to be a common pathway by which SCRD and stress increase Aβ production and promotes the development of AD. What remains unclear is whether stress and SCRD independently activate the HPA axis, stress causes SCRD leading to HPA axis activation, or SCRD causes stress and therefore HPA axis activation.

4.2. Microglia {#sec4.2}
--------------

A recent intense focus in AD research has involved elucidating the role of neuroinflammation, which is one of the defining hallmarks of AD ([@bib177]). Indeed, there have been multiple studies targeting inflammation as a therapeutic treatment for AD. Specifically, microglia play an essential role in the initiation and progression of neuroinflammation. In fact, it is believed that the overactive and constant activation of microglia-mediated pruning could be the cause of the irreversible synaptic loss. Microglia is as an ideal target for studying the disease mechanism and is a "druggable" target. Microglia are the resident macrophages in the CNS. Using combination of genetic manipulation and in-vivo life microscopy imaging revealed that microglia constantly survey the neuronal milieu and when required phagocytose dendrites such as during development or when marked for pruning ([@bib120]). Together with the complement system, microglia play an essential role in synaptic pruning and sculpting of synapses in the brain ([@bib98]).

Sleep disruption and stress also affect microglia function. Sleep loss induces microglia activation and astrogliosis in the mouse cerebral cortex ([@bib10]; [@bib287]). Furthermore, chronic, but not acute, sleep loss promotes microglia activation without neuroinflammation and loss of synapses ([@bib10]). This loss of synapses, and eventually the loss of neurons, have been consistently reported and widely accepted as pathological hallmark of AD ([@bib233]). Remarkably, a novel and non-invasive approach to activate microglia using light pulses (40 Hz) to the eyes significantly reduces Aβ plaque loads and improves cognitive function in mice. The mechanism is not fully understood but thought to activate microglia and phagocytose Aβ plaques in the visual cortex of an AD mouse model ([@bib103]). In addition, ablation of the prostaglandin E2 receptor, an activator of microglia, results in reduced AD pathology and improved cognitive function ([@bib106]). Physiological stress induces activation of microglia, and mice subjected to chronic restraint have more Iba-positive microglia, indicating more activated microglia proliferation ([@bib289]; [@bib269]). Taken together, stressors such as sleep deprivation and circadian disruption activate microglia, which may result in excessive synaptic pruning and neuronal loss and ultimately AD.

4.3. Melatonin {#sec4.3}
--------------

Another important converging point between stress and circadian rhythm is melatonin. Melatonin regulates many circadian aspects including sleep-wake cycle and protects cells against oxidative stress. Contrary to conventional thoughts, other localized structures/organs also produce melatonin, such as the gut, skin, platelets, bone marrow and others ([@bib23]; [@bib243]; [@bib33]; [@bib26]; [@bib250]). Melatonin is synthesized from tryptophan by three key enzymes: tryptophan hydroxylase, arylalkylamine-N-acetyltransferase and hydroxyindole-O-methyl-transferase. The mRNA level of these three enzymes, and their corresponding protein levels, oscillate with the day/night rhythm ([@bib12]). Due to the lack of melatonin storage, the plasma melatonin concentration reflects the activity of the pineal gland. Human melatonin levels peak at around 03:00 AM and decline to a barely detectable level during the day ([@bib46]). Melatonin increases SWS and possibly stimulates the release of growth hormone and neurotrophin ([@bib176]).

Melatonin has many characteristics of a free radical scavenger, and is excellent at reducing oxidative stress ([@bib71]). In particular, many studies have shown that melatonin protects neurons from secondary damage following ischemia ([@bib160]; [@bib128]; [@bib124]; [@bib277]; [@bib197]). Melatonin also protects primary neurons *in vitro* from damage when incubated with synthetic Aβ peptides through an undefined mechanism ([@bib197]). Collectively, melatonin protects neurons against oxidative stress, ischemia, depression, and cognitive impairment. However, the effect of stress on melatonin production is largely unknown, although stress has been reported to decrease the level of melatonin in trout ([@bib151]).

The link between melatonin and AD has been well characterized; low melatonin levels at night were noticed in the aging population and correlated with cognitive impairment ([@bib242]) ([@bib147]). The melatonin levels in the prefrontal cortex is inversely correlated with an individual\'s Braak pathology stage, such that lower melatonin associates with a higher Braak stage (indicating more severe AD) ([@bib147]). In keeping with this, Aβ peptides impede melatonin synthesis in the pineal gland and interfere with melatonin receptor signaling via the ERK/MAPK pathway ([@bib30]). Given the relationship between melatonin and AD, melatonin has been examined as a treatment in AD. Such studies have reported positive, though modest, effects of melatonin in cognitive deficits and attenuating behavioral disturbances ([@bib216]; [@bib81]).

4.4. Hypocretin/orexin {#sec4.4}
----------------------

Hypocretin ([@bib138]) and orexin ([@bib221]) are the same neuropeptide that were cloned in parallel by two independent research groups in 1998. One of the primary functions of orexin is to promote and stabilize wakefulness ([@bib123]; [@bib255]). The orexinergic neurons in the hypothalamus project their fibers to many different nuclei that govern sleep-wake cycle such as the LC, septal nuclei, medullary reticular formation, and others ([@bib204]). Stressors such as foot shock and restraint increase c-Fos expression in hypocretinergic neurons; however, only restraint stress elicits an increase in orexin mRNA levels ([@bib214]). The effect of stress on increased c-Fos expression is nullified in CRH-Receptor 1 (CRHR1) knockout mice, suggesting that an increase in orexin occurs through activation of the CRH pathway ([@bib286]). Subsequent studies have shown that there is an intricate connection between orexin and the HPA axis. Furthermore, higher levels of interstitial Aβ were observed in forced wakefulness using orexin; conversely, lower levels of interstitial Aβ were observed in forced sleep using almorexant, an orexin antagonist ([@bib117]). Moreover, deletion of orexin receptors in the *APP/PS1/OR* knockout mouse shows a significant reduction of Aβ plaque deposition in 3.5- and 8-month old mice. Mice lacking orexin receptors sleep significantly more while plaque deposition was significantly abated ([@bib218]). When these orexin receptor knockout mice were sleep deprived, amyloid plaque burden worsened, further supporting the role of sleep on AD pathogenesis sleep. In addition, orexin has been shown to modulate circadian oscillation of AD risk genes such as *APOE, ABCA1, BACE1, GSKβ*, and others ([@bib155]). In summary, these results demonstrate the role of orexin in sleep regulation, its interaction with stress through the HPA axis, and most recently that orexin regulates the oscillatory expression of the AD risk genes. These results warrant the necessity for further investigation of orexin in AD pathogenesis ([@bib143]).

4.5. ERK/MAPK signaling pathway {#sec4.5}
-------------------------------

Memory impairment is the most prominent type of cognitive dysfunction and the first symptom in AD. Memory formation is a multistep process that requires encoding, consolidation, retrieval, reconsolidation, and extinction ([@bib241]; [@bib6]; [@bib34]). The influence of stress on memory has been well studied (for reviews, see ([@bib232]; [@bib68])). Briefly, short-term stress may enhance memory while chronic long-term stress impairs memory. Chronic stress elevates cortisol levels, which subsequently decrease the number of dendritic synapses. Stress and memory impairment are part of the vicious cycle, where memory impairment causes stress and stress causes memory impairment in AD patients.

The molecular pathways that intersect between memory and circadian rhythm has been intensively reviewed ([@bib244]; [@bib293]; [@bib59]). The ERK/MAPK pathway is at the center of memory consolidation. Notably, levels of phospho-ERK, cAMP and phospho-CREB, and the activity of PKA and MEK were observed to oscillate in a circadian manner ([@bib60]). Remarkably, multiple approaches, including pharmacological, genetic and behavioral tests were utilized to demonstrate that the oscillation of cAMP/PKA/MAPK/CREB is crucial for memory maintenance. Moreover, the cAMP/PKA/ERK/CREB signaling pathway in the hippocampus is regulated by the SCN ([@bib205]). Consistently, ablating the *Bmal1* gene resulted in reduced Per1 and pERK levels, dysrhythmia in sleep-wake, and impaired spatial and associative memories compared to controls ([@bib280]). Interestingly, the cAMP/PKA/ERK/CREB signaling pathway is specifically increased during REM sleep ([@bib154]). In addition, Per1 mediates nuclear shuttling of a CREB kinase, P90RSK, and plays a major role in memory formation ([@bib212]). The role of APP and Aβ on memory are inconclusive, as many studies have shown that short term application of Aβ peptides has a positive effect on long-term potentiation (the molecular correlate of memory) and memory formation ([@bib72]). Yet, long term effects of Aβ are detrimental to memory and cognition. In short, stress has been shown to effect memory through the ERK signaling pathway ([@bib237]), and the circadian rhythm influences this same signaling pathway ([@bib163]; [@bib150]; [@bib104]). Furthermore, in AD mouse model, ERK appears overactivated, and pharmacological inhibition of ERK improves memory ([@bib64]). Downstream of the ERK pathway, AD mouse model shows reduction of pCREB level, which leads to a reduction of CRE-mediated transcription, resulting in recognition memory impairment ([@bib8]). Aß (1--42) reportedly interferes with the ERK signaling pathway and impairs working memory ([@bib63]). Taken together, the ERK signaling pathway is disrupted in AD perhaps due to Aß (1--42) inference binding ([@bib99]). Therefore, the ERK/MAPK signaling pathway plays an integral role not only for memory consolidation but also is a common pathway downstream of stress, circadian rhythm and sleep.

4.6. Gut microbiome: the unexpected union of stress and circadian rhythm {#sec4.6}
------------------------------------------------------------------------

The gut microbiome has recently become an intense field of research interest. Gut bacteria (10^14^) outnumber total cells in humans (3.7 × 10^13^), and their collective genome outnumbers the human genome 100 to 1 ([@bib48]). The gut microbiota\'s density is 10^12^ cells/ml, and their cumulative mass is around 1.5 kg. Besides facilitating digestion and providing vitamin B and K, the gut microbiota plays many essential roles in inflammation and brain protection by secreting brain derived neurotrophic factor ([@bib161]). In particular, the gut-brain axis has been implicated in neurodegenerative diseases such as Parkinson\'s disease and AD ([@bib95]). Comprehensive reviews of the gut-microbiota are covered in these articles ([@bib158]; [@bib69]; [@bib299]). Remarkably, the gut microbiota display a circadian rhythm in both the amount and the composition of the microbiota examined at the transcriptomic level. Furthermore, when the host has been subjected to a jetlag circadian paradigm, the circadian rhythm of gut microbiota also changes. This indicates a crucial role of the SCN master clock on the circadian rhythm of gut microbiota ([@bib265]). Although the role of the circadian rhythm on microbiota has only recently been examined, the role of stress on gut microbiota was explored many decades ago. Specifically, rats subjected to multiple stressors (i.e. wet cage bedding) for two days had decreased Lactobacilli and fusiform-shaped bacteria in the small and large bowels while the total number of anaerobic was unchanged ([@bib263]).

Recently, a potential association between gut microbiota and AD has begun to emerge, largely from studies of mouse models of AD. Several experiments have suggested that gut microbial dysbiosis may contribute to AD pathogenesis. First, the 16s rRNA sequence of the gut microbiome in an AD mouse model was significantly different from the microbiome of a control mice ([@bib299]). Second, treatment of a mouse model of AD with antibiotics ameliorates AD pathologies ([@bib172]). Thus, immune-activated factors released from the gut microbiota are thought to cause inflammation in the brain and exacerbate AD pathology. Reducing the source of inflammation with a broad-spectrum antibiotic reduces Aβ plaques ([@bib172]). Consistently, AD mice housed in a germ-free environment, essentially eliminating gut microbiota from birth, show a similar reduction in Aβ plaques ([@bib83]). Remarkably, germ-free AD mice that received microbiota from an AD mouse housed in normal conditions had worse AD pathologies. In contrast, microbiota from control mice housed in normal conditions transplanted into germ-free AD mice decreases Aβ plaques. A bacteriotherapy approach of feeding probiotics to a mouse model of AD reduced Aβ plaques, inflammatory signals and attenuated cognitive decline ([@bib17]). Finally, in a first human study, feeding probiotics to AD patients improved their cognitive functions ([@bib1]). Collectively, these results support the novel hypothesis that bacteriotherapy could potentially serve as a therapeutic intervention to delay the progress of AD. Both stress and circadian disruption have numerous effects on the gut microbiome ([@bib161]), and a few initial studies indicate that modifying the gut microbiome has the potential to improve cognition in mouse models of AD and patients. The gut microbiome is therefore an important target in the search of modifying the disease course of AD.

5. Conclusion and future directions {#sec5}
===================================

In summary, SCRD can either independently or cooperatively with stress exacerbate AD pathology. SCRD and stress worsen AD pathology by concomitantly increasing production, decreasing clearance of Aβ, or both. SCRD and stress converge at multiple signaling pathways. Intriguingly, all of these converging points are under the control of sleep and the circadian rhythm. Thus, therapeutic strategies should incorporate new insights to approach through different lens, through which we can ameliorate SCRD in hope of abating the disease progress.

We envision that sleep and circadian rhythm disruption assessment might also be used as part of tool for detecting and mitigating risk for AD. Therapies aimed at improving sleep and circadian rhythm function, which by corollary decrease stress, may be necessary to prevent or limit progression of AD. Stress-reduction strategies can also improve sleep and perhaps could be helpful for preventing AD. Approaches to modifying circadian rhythm such as lengthening the photoperiod showed a significant increase of lifespan in a neurodegenerative disease mouse model ([@bib180]), suggesting that circadian rhythm modification could provide a tangible therapeutic avenue. Alternatively, small molecules could be used to modulate the biological clock and mitigate SCRD ([@bib37]). Furthermore, interventional behavior modifying approaches such as, physical activity, and bright light therapy have shown limited successes ([@bib167], [@bib168]). Lastly, phototherapy in combination with melatonin has shown some successes in improving cognitive functions. Logically, combinatorial approach such as early detection of the disease, bright light therapy and melatonin to restore circadian rhythm, stress-reduction techniques, and modification of the gut microbiome, may be necessary to prevent and treat AD.
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